Silver Spring, Md. — After two nine-hour sessions on July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend that six peptide bulk drug substances advance to the next stage of evaluation for possible inclusion on the list of bulk drug substances that may be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. The votes were advisory; FDA staff will now integrate committee input with pharmacovigilance data, labeling feasibility, and state-board enforcement patterns before any final listing decision.
The six peptides are: BPC-157 (body protection compound fragment), KPV (Lys-Pro-Val), TB-500 (referring to thymosin beta-4–related sequences used in compounding nominations), MOTS-c (mitochondrial open reading frame peptide), Epitalon (Ala-Glu-Asp-Gly tetrapeptide), and Semax (ACTH(4-10) analog). Each had been nominated with docket comments ranging from patient access advocacy to sharp warnings about subcutaneous use without approved monographs.
How PCAC reached its decisions
For each substance, FDA reviewers presented a standardized packet: proposed dosing ranges seen in compounded products, reported adverse events from FAERS and literature, physicochemical characterization challenges, and whether a USP or NF monograph exists or is in development. Committee members then voted on three questions: (1) whether there is a clinical need not met by approved drugs, (2) whether compounding can be conducted to produce a safe product, and (3) whether the substance should be placed on the 503A bulks list for further notice-and-comment.
Discussions were substance-specific. BPC-157 generated the longest debate—committee members cited animal wound-healing literature alongside the absence of controlled human trials and concerns about immunogenicity of impure lots. TB-500 prompted questions about sequence identity because compounders variously reference thymosin beta-4 fragments with different chain lengths. MOTS-c discussions centered on mitochondrial penetration claims and stability in aqueous formulations. Epitalon and Semax, both with histories in overseas markets, raised CNS penetration and blood–brain barrier transport questions. KPV, often positioned for inflammatory dermatology compounding, was viewed as analytically simpler but still lacking approved drug comparators in the U.S.
Stakeholder reaction
The American Society of Health-System Pharmacists submitted comments emphasizing that list placement should require validated potency assays and maximum beyond-use dating supported by stability data—not anecdotal clinic protocols. A coalition of wellness clinics argued that patient harm arises from "gray market" vials rather than licensed 503A pharmacies, urging FDA to distinguish compounding quality standards from outright prohibition.
Research peptide trade groups, while not formal parties in the 503A process, issued parallel statements reminding buyers that 503A compounded drugs, 503B outsourced products, and research-use-only catalog peptides fall under different regulatory frameworks. A recommendation to evaluate a bulk substance for 503A is not approval, not a USP monograph, and not authorization for consumer self-injection of unverified research powders.
Timeline and practical impact
FDA typically publishes Federal Register notices within weeks of PCAC meetings, opening additional comment windows before final bulks-list updates. State boards of pharmacy may continue enforcing stricter local rules regardless of federal list changes—California and New York historically diverge from minimum federal permissiveness on peptide compounding.
For laboratory purchasers, the July 2026 PCAC outcome changes little on the bench: identity testing, endotoxin control, and explicit RUO labeling remain the baseline. If anything, the meeting increased scrutiny on sequence confirmation for BPC-157 and TB-500 lots because regulatory attention tends to cascade into supplier questionnaires—even for customers who never compound drug products.
Substance reference (for readers tracking nomenclature)
- BPC-157: Pentadecapeptide derived from gastric juice protein fragments; common research interest in tendon and GI mucosal models.
- KPV: Tripeptide α-MSH fragment studied in inflammatory pathway models.
- TB-500: Colloquial name for thymosin beta-4–related sequences; identity must be sequence-specific in COAs.
- MOTS-c: Mitochondrial-encoded peptide implicated in metabolic regulation research.
- Epitalon: Synthetic tetrapeptide associated with telomerase and circadian research literature.
- Semax: Heptapeptide nootropic research compound; not interchangeable with ACTH formulations.
Radiptide materials referenced in educational content are sold exclusively for laboratory and in vitro research. They are not compounded drug products and are not intended for human or veterinary use.